How gut bacteria affect cancer treatment effectiveness
Improvement of cellular immunotherapy during dysbiosis- Resubmission
This study is looking at how changes in gut bacteria caused by antibiotics might affect the success of immunotherapy for patients with advanced melanoma, with the hope of finding ways to improve treatment results for those who need it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-11059705 on NIH RePORTER |
What this research studies
This research investigates the impact of antibiotic-induced changes in gut bacteria, known as dysbiosis, on the effectiveness of cellular immunotherapy for melanoma patients. By understanding how these changes affect the immune system and tumor microenvironment, the researchers aim to develop strategies to enhance the response to immunotherapy. The study focuses on advanced melanoma, where current treatment responses are only about 50%. The goal is to identify ways to overcome the negative effects of dysbiosis and improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma who are undergoing or considering cellular immunotherapy.
Not a fit: Patients with early-stage melanoma or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved effectiveness of immunotherapy for melanoma patients, potentially increasing survival rates.
How similar studies have performed: While the specific approach of addressing dysbiosis in relation to immunotherapy is novel, similar research has shown that gut microbiome health can influence treatment outcomes in cancer therapies.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Dings, Ruud P.m. — Univ of Arkansas for Med Scis
- Study coordinator: Dings, Ruud P.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.